Sisvel Launches Its Cellular IoT Patent Pool
Sisvel International S.A. (Sisvel) announced today the launch of its Cellular IoT (C-IoT) Patent Pool consisting of 20 patent owners.
The C-IoT patent pool offers a single solution to license standard essential patents (SEPs) that are essential for the use of the cellular LPWAN standards LTE-M and Narrowband IoT (NB-IoT). Sisvel is joined in the pool by ASUSTek, Datang, Ericsson, ETRI, Innovative Sonic, JVCKENWOOD, KDDI, MediaTek, Mitsubishi Electric, NTT DOCOMO, Optis Cellular, Optis Wireless, Orange, Pantech, Shanghai Langbo, Sony Group Corporation, Telefónica, Unwired Planet and one additional company to be announced soon. The pool remains open for new participants that hold relevant patents. The C-IoT pool’s initial main focus will be on smart meters and asset trackers.
“The IoT market has been in development for about a decade, however only now we see clear early signs of widespread roll-out.” said Mattia Fogliacco, President of the Sisvel Group. He continues: “The LTE-M and NB-IoT technologies are an obvious pick to connect products and services, and with this pool, available already in an early phase of technology adoption, we will remove a lot of questions and concerns by giving easy, transparent and reasonable access to the patents that the creators of the technology hold.”
“It has been a pleasure putting this pool together, as so many parties with diverse background and business models showed resolve and common interest in creating a pool in the LPWAN IoT space.” said Sven Törringer, the program manager of the Sisvel C-IoT patent pool. He added: “This has been a harmonious process and we are convinced that the offer we bring to the market will not only reduce friction and concerns, but rather boost the interest in the adoption of the LTE-M and NB-IoT standards in IoT products, allowing for swift investments in this sense.”
LTE-M and NB-IoT are cellular LPWAN IoT standards that followed out of the 4G LTE standard. They offer a solution for low power connectivity of IoT products, that may compete with the functionality offered by a number of other technologies, such as LoRaWAN, Sigfox, WiFi, MIOTY, Bluetooth, various mesh network technologies, etc, and combinations thereof. By offering a clear framework for obtaining licenses under the pool’s portfolio of LTE-M and NB-IoT SEPs, Sisvel is making it easier for manufacturers of IoT devices to make a balanced choice between the available technologies. The Sisvel pool has committed itself to make the terms of LTE-M and NB-IoT competitive, to encourage the use of the LPWAN cellular IoT standards, helping to achieve a level playing field.
Further information about the C-IoT patent pool is available on Sisvel’s website: https://www.sisvel.com/licensing-programs/wireless-communications/cellular-iot/introduction. For more details you may contact Sisvel at the following e-mail address ciot@sisvel.com.
About Sisvel
Sisvel International S.A. is the holding company of the Sisvel Group. Sisvel is a world leader in fostering innovation and managing IP. The group identifies, evaluates and maximizes the value of IP assets for its partners around the world, providing firms with a revenue stream which can be reinvested in innovation for the generation of future revenues. Sisvel has 40 years’ experience in the management of successful patent portfolios, including those relating to audio compression standards (MP3 and MPEG audio), as well as broadcasting and digital terrestrial television standards maintained by the Digital Video Broadcasting Project. Currently Sisvel operates patent pools and joint licensing programs in the fields of mobile communication, wireless local area networking 802.11, video coding and digital video broadcasting.
www.sisvel.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005073/en/
Contact information
Media Contact Sisvel Group
Giulia Dini
Communications Manager
Tel: +34 93 131 5570
giulia.dini@sisvel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom